abilify asimtufii
(Aripiprazole)Otsuka America Pharmaceutical, Inc
Usage: ABILIFY ASIMTUFII is indicated for the treatment of schizophrenia in adults and for maintenance monotherapy of bipolar I disorder in adults.
Neurology & Sleep drugs
133 results
abilify maintena
(aripiprazole)Otsuka America Pharmaceutical, Inc.Usage: ABILIFY MAINTENA (aripiprazole) is indicated for the treatment of schizophrenia and as maintenance monotherapy for bipolar I disorder in adults.acthar
(Repository Corticotropin)Mallinckrodt ARD LLCUsage: Acthar Gel is indicated for treating infantile spasms in infants under 2, acute exacerbations of multiple sclerosis in adults, and as adjunctive therapy for various rheumatic disorders. It is also used for certain collagen diseases, severe dermatologic and allergic conditions, ophthalmic inflammatory diseases, symptomatic sarcoidosis, and nephrotic syndrome.aimovig
(erenumab-aooe)Amgen IncUsage: AIMOVIG is indicated for the preventive treatment of migraines in adults.ajovy
(fremanezumab-vfrm)Teva Pharmaceuticals USA, Inc.Usage: AJOVY is indicated for the preventive treatment of migraines in adults.ambien
(zolpidem tartrate)sanofi-aventis U.S. LLCUsage: AMBIEN (zolpidem tartrate) is indicated for the short-term treatment of insomnia, specifically for difficulties with sleep initiation. It effectively reduces sleep latency for up to 35 days, as demonstrated in controlled clinical studies lasting 4–5 weeks.ambien
(zolpidem tartrate)sanofi-aventis U.S. LLCUsage: AMBIEN CR (zolpidem tartrate extended-release tablets) is indicated for the short-term treatment of insomnia, particularly for difficulties with sleep onset and/or maintenance, as measured by wake time after sleep onset. Clinical trials supporting its efficacy lasted up to 24 weeks.amondys 45
(casimersen)Sarepta Therapeutics, Inc.Usage: AMONDYS 45 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene suitable for exon 45 skipping. Approval is based on increased dystrophin production in skeletal muscle, with continued approval subject to further confirmation of clinical benefit.ampyra
(Dalfampridine)Merz Pharmaceuticals, LLC, a subsidiary of Merz Therapeutics GmbHUsage: AMPYRA is indicated for improving walking in adult patients with multiple sclerosis (MS), as evidenced by increased walking speed.amvuttra
(VUTRISIRAN)Alnylam Pharmaceuticals, Inc.Usage: AMVUTTRA is indicated for treating the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.